POLICIES GOVERNING ICRF ACCELERATION GRANTS

The Israel Cancer Research Fund (ICRF) is a voluntary charitable organization that receives its total income from private donations. The goal of the ICRF is to advance cancer research and the training of Israeli scientists in Israel.

The ICRF has always been committed to supporting world class cancer research that contributes to improved cancer treatment and can lead to cancer cures. With their creative skills and innovative approaches, ICRF-funded investigators have discovered the proteasome and proteasome-mediated proteolysis, therapeutic targets for chronic myelogenous leukemia, and discovered or elucidated cancer-related functions of the tumor suppressors p53 and ATM, among others. Each of these findings has contributed to new drugs or ideas for treating cancer, and these investigators are widely recognized by the international community.

ICRF Acceleration Grants continue in that tradition. Successful applications will propose innovative approaches that have the promise of pioneering new ways of thinking about cancer biology and therapeutics. Preliminary data are not a prerequisite, but applicants are encouraged to provide data from disparate sources to support the rationale upon which the new concepts are derived. Multi-investigator applications and interdisciplinary approaches are encouraged, but not required. Of paramount importance is the promise of accelerating progress in our understanding of the biology underlying cancer and providing new knowledge that will rapidly enhance the development of innovative diagnostics and therapeutics.

Duration and Amount of the Grant

Acceleration Grants are awarded for two (2) years for $70,000 per year, as determined by the Scientific Review Panel and the availability of funds. Funding for the second year is contingent upon progress in the preceding funding period, as documented in a progress report due on June 30.

To Apply for an Acceleration Grant

- **Letter of Intent (LOI):** Because of the innovative focus of the Acceleration Grant program, the ICRF requires that interested investigators submit by December 1 a letter of intent (LOI) outlining the proposed research in brief. LOIs will be reviewed by a specially-constituted ICRF Scientific Review Panel to identify proposals that best fit the goals of the Acceleration Grant program.

- **Submission of a Full Proposal:** Investigators who outline projects of exceptional novelty and promise in the LOI will be invited to submit a full proposal (deadline to be determined). Acceleration Grant applicants who are invited to submit a full proposal will be notified of funding decisions on July 1 and their grants will be activated on September 1.

Further Information

Additional information and templates for applying for an ICRF cancer research grant can be downloaded from our website, www.icrfonline.org/apply-for-a-grant/.

For information on **General Policies Governing ICRF Grants**, including fiscal requirements for sponsoring institutions, please see the following pages.

**Questions?** For any questions or problems, please send an E-mail message to: ellen.rubin@icrfny.org
GENERAL POLICIES GOVERNING ICRF GRANTS

The Israel Cancer Research Fund (ICRF) is a voluntary charitable organization that receives its total income from private donations. The goal of the ICRF is to advance cancer research and the training of Israeli scientists in Israel.

The ICRF supports clinical and basic research and research training, which must relate to cancer. To apply for an ICRF-funded grant, an investigator must be a citizen of Israel (proof of Israeli citizenship must be furnished upon request). Typically, all research must be conducted in Israel. However, in the case of certain collaborative grants, joint applications are considered from co-investigators, only one of whom is an Israeli citizen proposing research that will be conducted at an Israeli institution.

Timetable for the Submission and Awarding of Grants

<table>
<thead>
<tr>
<th>RECEIVED BY THE ICRF</th>
<th>NOTIFICATION OF DECISION</th>
<th>ACTIVATION OF GRANT</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 31, 2020, 11:59PM EST</td>
<td>July 1, 2021</td>
<td>September 1, 2021</td>
</tr>
</tbody>
</table>

- Only one (1) grant application per principal investigator will be accepted for each submission deadline.
- Applications that do not provide all required information, as specified, will be rejected automatically, and will not be processed or reviewed.
- A single investigator may not hold two ICRF grants concurrently. If you are currently the recipient of ICRF funding, you may only apply for another ICRF grant, if the start date for the new application falls after the termination date for current funding.

Each application is reviewed by a Scientific Review Panel and evaluated for:
1. scientific merit, innovation, and potential significance for advancing the understanding, diagnosis and/or treatment of cancer;
2. the qualifications of the applicant, based on prior training, demonstrated expertise, and scientific productivity;
3. progress resulting from previous funding, both for renewals and new proposals, submitted by investigators who have previously received ICRF funding;
4. for proposals that are mentored, letters of commitment from mentors and the utility of the mentoring plan;
5. facilities, materials, resources and scientific environment available for the project, and the duration of such availability, as identified by the investigator and confirmed in writing by the institutional grants office and/or the investigator’s department chair.

The rankings and recommendations of the Scientific Review Panels are presented to the International Scientific Council for further consideration and then to the ICRF Board of Trustees for final approval.

Additional information and templates for applying for an ICRF research grant can be downloaded from our website, www.icrfonline.org/apply-for-a-grant/.

Questions? For any questions or problems, please send an E-mail message to: ellen.rubin@icrfny.org
Fiscal Requirements and Considerations for the Sponsoring Institution

An applicant for ICRF funding must hold a position at a sponsoring Israeli institution able to provide research space and administrative infrastructure for the project.

In addition to the applicant’s signature, each submitted application must be signed by an authorized institutional official in order to signify the ability and willingness of the sponsoring institution to provide research space and budgetary oversight to the project.

ICRF funds that support Research Professorships, Project Grants, Acceleration Grants, Research Career Development Awards (RCDAs), Clinical Research Career Development Awards (RCDAs) and Postdoctoral Fellowships may only be used for work performed in Israel.

ICRF funds are to be used for actual direct expenses (salary, supplies, etc.) connected with the project. No overhead, clerical or other administrative charges can be made by the institution against the grant funds. Travel expenses are not allowed for Research Professorships, Project Grants or Acceleration Grants. A maximum of $1,000 per year in travel expenses may be budgeted for, CRCDAs, and Postdoctoral Fellowships.

The sponsoring institution must maintain a separate account for each grant funded by the ICRF. This account must be available for audit at any time by representatives of the ICRF.

A report of all expenditures, detailing the utilization of the funds (salaries, supplies, etc.), must be submitted to ICRF annually. These reports are due by September 30. Reminder notices will be sent directly to the institution by the ICRF. Grant payments will be suspended, if these reports become overdue.

Continuation of Grants

Initial grants are made for one year. Funding for subsequent years is contingent upon progress, as documented in a progress report due annually on June 30. Grant payments will be suspended, if these reports become overdue.

Renewal of Grants

The ICRF permits recipients of some grants to apply for continued funding. Renewal applications are evaluated by the Scientific Review Panels along with applications for new funding, and they must be competitive with those applications to be renewed. Renewal applications should be submitted by the December 31 deadline during the final active year of the grant to avoid a lapse in funding.

Special Leave

A. Special leave for work in another institution (with continuing support from the grant) may be permitted, if directly related to the purpose of the grant. If such leave does not exceed three months, only local institutional approval is required. For a longer period, prior approval of the ICRF is required. To obtain approval, the grantee must submit to the ICRF at least six (6) months prior to the leave, a letter describing how the grantee will supervise his/her laboratory during this period. This letter must be countersigned by the grantee’s department head and the appropriate institutional official. Such leave may not exceed 12 months.

B. Leave without grant support requires the prior approval of the ICRF and will be permitted only in unusual situations. Such leave may not exceed 12 months. Support from other sources is permissible during the period of leave, and such leave does not reduce the total number of months of program support for which a grantee is eligible.

Special Conditions

Should the ICRF grantee or the sponsoring institution specified by a grant vacate the project, the ICRF will automatically void the grant and terminate funding. Failure of the sponsoring institution to notify the ICRF of such vacancy will allow the ICRF to recover funds in toto.
Changes and Amendments

Any changes or amendments to the original grant must be approved in writing by the ICRF.

Termination or Change of Institution

1. If a grantee institution plans to terminate a grant, the ICRF must be notified in writing at the earliest possible time so that appropriate instructions can be given for termination.

2. If an individual is moving to another eligible institution, grant support may be continued, provided:
   a. A new application is submitted by the new institution on behalf of the individual for review by the ICRF together with a letter of release from the existing institution;
   b. The period of support requested is only for the time remaining within the duration of overall funding;
   c. The new application is submitted at least six (6) months prior to the requested effective date to allow the necessary time for review.

3. The ICRF may discontinue a grant upon determination that the purpose or terms of the grant are not being fulfilled. In the event a grant is terminated, the ICRF shall notify the sponsoring institution and the grantee in writing of its decision, the reasons therefore, the effective date, and the right to appeal the decision.

4. A final progress report and expenditure report are required within 60 days of termination of a grant.

Biohazards and Protection of Human and Animal Subjects

It is the responsibility of the institution that sponsors a grant to provide oversight that safeguards the rights and welfare of human and animal subjects of research supported by the ICRF, and to ensure that investigators use caution in dealing with any toxic materials or potential biohazards.

Grants for projects involving human subjects and/or animals require prior review and approval of the appropriate institutional committee. Approvals must be written in English and submitted along with the ICRF application. For this certification to be valid, the date of the review may not precede the submission date by more than one year.

Patents

No patent application for work done under an ICRF grant shall be filed by the sponsoring institution or by any individual investigator engaged in this research without prior consultation with and written approval of the ICRF.

Publications

Publications resulting from projects supported by the ICRF must contain the following acknowledgment: “This study was supported by [insert grant type] from the Israel Cancer Research Fund.” (Please note that our name ends in “Fund,” not “Foundation!”)

Grantees should send electronic copies of publications carrying the above credit line to the ICRF International Executive Office in New York as soon as possible after publication.

# # #